Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

InflammaGen Begins Clinical Trial of Treatment for Multi-Organ Failure

publication date: Mar 15, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
InflammaGen™ Therapeutics, a San Diego clinical-stage company, will start a 200-patient Phase II trial in the US of its InflammaGen Shok-Pak as a treatment and prevention of multi-organ failure (MOF). To develop the product outside the US, InflammaGen has retained ChinaBio® to assist the company with its efforts to bring Shok-Pak to China. ChinaBio has several similar engagements underway with other US and European companies, helping them secure co-development partners and funding in China for their clinical stage assets. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...